Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions David Burrows
Genzyme General DivisionGENZTOP PICKJan 12, 2005
Has grown very well over the last 3 years against an industry that's had a difficult time. Risk level is relatively low. A better way to develop new drugs as opposed to the old line drug companies.
David BurrowsOwned
$59.91
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
PAST TOP PICK
(A Top Pick Jan 12/05. Down 1%.) The bio-techs are about the best performing group over the last little while. Diversified product line. Have a great revenue line. Still likes.
David BurrowsOwned
biotechnologypharmaceutical
PAST TOP PICK
(Top Pick Jan 12/05. Down 6%.) The pharmaceutical group has been out of favor. Has some good revenue growth.
David BurrowsOwned
biotechnologypharmaceutical
